C. Jillian Tsai, Lead of Palliative Radiotherapy and Oligometastases Program (PROP) at Princess Margaret Cancer Centre, posted on X:
“Nice commentary by Musaddiq Awan, James Caudell, David Sher, et al – caution needed when applying KEYNOTE-689 data especially for CPS <10. risks of progression before surgery, toxicity, and cost, with unclear OS benefit.”
Title: Notably Off Key: Questioning the Clinical Benefit of Perioperative Immunotherapy for Resectable Head and Neck Squamous Cell Carcinoma After KEYNOTE-689
Authors: Musaddiq Awan, James Caudell, Stuart Wong, Baran Sumer, Kedar Kirtane, Joseph Zenga, David Sher
Read the article: here.
Other articles featuring C. Jillian Tsai on OncoDaily.